Preview Mode Links will not work in preview mode

Sep 15, 2014

1) Course of psychiatric symptoms and global cognition in early Parkinson disease and 2) Topic of the month: Management of sports concussion. This podcast for the Neurology Journal begins and closes with Dr. Ted Burns, Section Editor Podcasts, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Matt Barrett interviews Dr. Dan Weintraub about his paper on the course of psychiatric symptoms and global cognition in early Parkinson disease. Dr. James Addington is reading our e-Pearl of the week about KCNQ2 in early onset epileptic encephalopathy. In the next part of the podcast Dr. Stephen Donahue interviews Dr. Michael Jaffee about the management of concussion after the diagnosis has been made and the recommendation for graduated return to play or normal activities. The participants had nothing to disclose except Drs. Barrett, Weintraub, Addington and Jaffee.Dr. Barrett receives research support from the Virginia Center of Alzheimer's and Related Diseases Research Award Fund.Dr. Weintraub serves as an editorial board member of Movement Disorders Journal and Journal of Parkinson's disease; serves on the scientific advisory boards of Pfizer Inc, Teva Pharmaceuticals Industries Ltd., Avanir Pharmaceuticals, Merck Serono, Lundbeck Inc., UCB, Bristol-Myers Squibb, Novartis, Clintrex, Theravance, Medication Non-profit-CHDI, ADCS; receives license fee payments from the University of Pennsylvania for licensing of questionnaire for impulsive-compulsive disorders in Parkinson disease and QUIP and QUIP-RS; gave expert testimony for defense in two lawsuits related to impulse control disorders in Parkinson disease; receives research support from Michael J. Fox Foundation, Department of Veterans Affairs, Novartis and the NIH.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Jaffee serves on the scientific advisory boards for WETA (Public Television) Brainline, U. S. Army Peer Review Alzheimer Research Program and the NIH translational research outcome consortium review.